Research record
Trametinib + hydroxychloroquine
A research strategy combining MEK inhibition with autophagy inhibition in NRAS melanoma.
What this is
A research strategy combining MEK inhibition with autophagy inhibition in NRAS melanoma.
Why it may come up
- has spread or locally advanced cannot be removed by surgery NRAS melanoma
What not to assume
- No dosing details in patient UI.
At a glance
Trametinib + hydroxychloroquine
- Type
- Targeted therapy
- Mutation result
- NRAS
- Where
- EU
- Evidence status
- In clinical trials
- Last checked
- 2026-05-20
What we know
- ClinicalTrials.gov lists NCT03979651 for trametinib plus hydroxychloroquine in NRAS melanoma.
What is unclear
- Public pages should not infer routine clinical use from this trial record.
Questions to ask
- Is this trial still relevant or completed?
- Would prior MEK inhibitor exposure affect a similar trial?
- What mechanism is being tested?
Related trial leads
NCT03979651
Trametinib plus hydroxychloroquine in NRAS melanoma
NRAS melanoma research lead involving MEK inhibition and autophagy inhibition.